Symbols / BNTX Stock $93.66 +0.34% BioNTech SE

Healthcare • Biotechnology • Germany • NMS
BNTX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Ugur Sahin M.D.
Exch · Country NMS · Germany
Market Cap 23.69B
Enterprise Value 10.28B
Income -1.25B
Sales 2.81B
FCF (ttm) -428.11M
Book/sh 87.09
Cash/sh 54.20
Employees 7,807
Insider 10d —
IPO Oct 10, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -17.00
PEG 0.05
P/S 8.44
P/B 1.08
P/C —
EV/EBITDA -8.63
EV/Sales 3.67
Quick Ratio 8.11
Current Ratio 8.80
Debt/Eq 1.62
LT Debt/Eq —
EPS (ttm) -5.97
EPS next Y -5.51
EPS Growth —
Revenue Growth -35.40%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-04
Earnings (prior) 2026-05-05
ROA -4.18%
ROE -6.66%
ROIC —
Gross Margin 78.65%
Oper. Margin -5.77%
Profit Margin -44.64%
Shs Outstand 252.88M
Shs Float 109.30M
Insider Own 57.43%
Instit Own 20.10%
Short Float 3.24%
Short Ratio 2.62
Short Interest 2.22M
52W High 124.00
vs 52W High -24.47%
52W Low 79.52
vs 52W Low 17.78%
Beta 1.37
Impl. Vol. 53.66%
Rel Volume 0.33
Avg Volume 1.15M
Volume 379.06K
Target (mean) $129.41
Tgt Median $131.63
Tgt Low $76.23
Tgt High $159.06
# Analysts 18
Recom Buy
Prev Close $93.34
Price $93.66
Change 0.34%
About

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$129.41
Mean price target
2. Current target
$93.66
Latest analyst target
3. DCF / Fair value
$-30.47
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$93.66
Low
$76.23
High
$159.06
Mean
$129.41

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-06 main Canaccord Genuity Buy → Buy $158
2026-05-06 main Wells Fargo Overweight → Overweight $140
2026-04-27 reit HC Wainwright & Co. Buy → Buy $130
2026-04-10 main Morgan Stanley Overweight → Overweight $126
2026-03-31 main HC Wainwright & Co. Buy → Buy $130
2026-03-11 main Morgan Stanley Overweight → Overweight $125
2026-03-11 main Canaccord Genuity Buy → Buy $171
2026-03-11 main Citigroup Buy → Buy $130
2026-03-11 main TD Cowen Hold → Hold $94
2026-03-11 main BMO Capital Outperform → Outperform $128
2026-03-10 main Jefferies Buy → Buy $138
2026-01-16 up Goldman Sachs Neutral → Buy $142
2025-11-10 main HC Wainwright & Co. Buy → Buy $140
2025-11-06 main UBS Neutral → Neutral $117
2025-10-23 main JP Morgan Neutral → Neutral $120
2025-10-10 main Morgan Stanley Overweight → Overweight $131
2025-09-22 main JP Morgan Neutral → Neutral $121
2025-09-08 reit HC Wainwright & Co. Buy → Buy $136
2025-08-14 main HC Wainwright & Co. Buy → Buy $136
2025-08-05 main Wells Fargo Overweight → Overweight $150
News
RSS: Latest BNTX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-22 POETTING SIERK Chief Operating Officer — 50,000 $110.56 $5,527,960
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
2,869.90
+4.32%
2,751.10
-27.96%
3,819.00
-77.94%
17,310.60
Operating Revenue
2,869.90
+4.32%
2,751.10
-27.96%
3,819.00
-77.73%
17,145.20
Cost Of Revenue
641.80
+18.57%
541.30
-9.75%
599.80
-79.97%
2,995.00
Reconciled Cost Of Revenue
641.80
+18.57%
541.30
-9.75%
599.80
-79.97%
2,995.00
Gross Profit
2,228.10
+0.83%
2,209.80
-31.36%
3,219.20
-77.51%
14,315.60
Operating Expense
2,868.80
-1.73%
2,919.20
+24.56%
2,343.60
+16.49%
2,011.80
Research And Development
2,104.90
-6.62%
2,254.20
+26.42%
1,783.10
+16.01%
1,537.00
Selling General And Administration
698.20
-2.03%
712.70
+21.39%
587.10
+8.48%
541.20
Selling And Marketing Expense
110.00
+62.00%
67.90
+8.29%
62.70
+5.38%
59.50
General And Administrative Expense
588.20
-8.78%
644.80
+22.96%
524.40
+8.86%
481.70
Salaries And Wages
—
—
—
153.70
Other Gand A
588.20
-8.78%
644.80
+22.96%
524.40
+8.86%
481.70
Other Operating Expenses
65.70
+237.74%
-47.70
-79.32%
-26.60
+59.94%
-66.40
Total Expenses
3,510.60
+1.45%
3,460.50
+17.57%
2,943.40
-41.21%
5,006.80
Operating Income
-640.70
+9.68%
-709.40
-181.02%
875.60
-92.88%
12,303.80
Total Operating Income As Reported
-1,404.90
-6.89%
-1,314.30
-290.37%
690.40
-94.54%
12,642.70
EBITDA
-653.80
-80.21%
-362.80
-126.35%
1,377.00
-89.49%
13,096.30
Normalized EBITDA
-254.80
+38.07%
-411.40
-138.85%
1,059.00
-91.48%
12,427.10
Reconciled Depreciation
382.80
+28.46%
298.00
+62.49%
183.40
+48.74%
123.30
EBIT
-1,036.60
-56.87%
-660.80
-155.36%
1,193.60
-90.80%
12,973.00
Total Unusual Items
-399.00
-920.99%
48.60
-84.72%
318.00
-52.48%
669.20
Total Unusual Items Excluding Goodwill
-399.00
-920.99%
48.60
-84.72%
318.00
-52.48%
669.20
Special Income Charges
-780.90
-18.03%
-661.60
-82600.00%
-0.80
+73.33%
-3.00
Other Special Charges
789.50
+20.09%
657.40
+2136.05%
29.40
+880.00%
3.00
Restructuring And Mergern Acquisition
-15.00
0.00
0.00
—
Write Off
6.40
+52.38%
4.20
+425.00%
0.80
—
Net Income
-1,136.10
-70.77%
-665.30
-171.51%
930.30
-90.14%
9,434.40
Pretax Income
-1,050.80
-55.05%
-677.70
-157.14%
1,186.10
-90.84%
12,954.10
Net Non Operating Interest Income Expense
-11.10
+34.32%
-16.90
-125.33%
-7.50
+60.32%
-18.90
Interest Expense Non Operating
14.20
-15.98%
16.90
+125.33%
7.50
-60.32%
18.90
Net Interest Income
-11.10
+34.32%
-16.90
-125.33%
-7.50
+60.32%
-18.90
Interest Expense
14.20
-15.98%
16.90
+125.33%
7.50
-60.32%
18.90
Interest Income Non Operating
—
437.60
+22.37%
357.60
+637.32%
48.50
Interest Income
—
437.60
+22.37%
357.60
+637.32%
48.50
Other Income Expense
-399.00
-920.99%
48.60
-84.72%
318.00
-52.48%
669.20
Gain On Sale Of Security
381.90
-46.23%
710.20
+122.77%
318.80
-52.57%
672.20
Tax Provision
85.30
+787.90%
-12.40
-104.85%
255.80
-92.73%
3,519.70
Tax Rate For Calcs
0.00
+1066.67%
0.00
-91.67%
0.00
-20.59%
0.00
Tax Effect Of Unusual Items
-83.79
-9678.19%
0.87
-98.73%
68.69
-62.26%
182.02
Net Income Including Noncontrolling Interests
-1,136.10
-70.77%
-665.30
-171.51%
930.30
-90.14%
9,434.40
Net Income From Continuing Operation Net Minority Interest
-1,136.10
-70.77%
-665.30
-171.51%
930.30
-90.14%
9,434.40
Net Income From Continuing And Discontinued Operation
-1,136.10
-70.77%
-665.30
-171.51%
930.30
-90.14%
9,434.40
Net Income Continuous Operations
-1,136.10
-70.77%
-665.30
-171.51%
930.30
-90.14%
9,434.40
Minority Interests
—
—
—
—
Normalized Income
-820.89
-15.13%
-713.03
-204.70%
680.99
-92.39%
8,947.22
Net Income Common Stockholders
-1,136.10
-70.77%
-665.30
-171.51%
930.30
-90.14%
9,434.40
Diluted EPS
-4.70
-69.68%
-2.77
-172.32%
3.83
-89.86%
37.77
Basic EPS
-4.70
-69.68%
-2.77
-171.58%
3.87
-90.02%
38.78
Basic Average Shares
241.70
+0.63%
240.18
-0.17%
240.60
-1.10%
243.28
Diluted Average Shares
241.70
+0.63%
240.18
-1.04%
242.70
-2.84%
249.79
Diluted NI Availto Com Stockholders
-1,136.10
-70.77%
-665.30
-171.51%
930.30
-90.14%
9,434.40
Depreciation Amortization Depletion Income Statement
—
—
—
—
Depreciation And Amortization In Income Statement
—
—
—
—
Insurance And Claims
—
—
—
21.30
Total Other Finance Cost
-3.10
—
7.90
+192.59%
2.70
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
21,988.60
-2.40%
22,529.70
-2.07%
23,006.30
-1.17%
23,279.10
Current Assets
16,146.60
-14.13%
18,803.50
-3.71%
19,527.30
-10.92%
21,922.00
Cash Cash Equivalents And Short Term Investments
14,877.20
-11.36%
16,783.60
+1.42%
16,549.00
+17.67%
14,064.50
Cash And Cash Equivalents
7,675.40
-21.37%
9,761.90
-16.31%
11,663.70
-15.94%
13,875.10
Cash Equivalents
6,848.20
-26.46%
9,311.90
-16.94%
11,210.60
-10.67%
12,549.90
Cash Financial
827.20
+83.82%
450.00
-0.68%
453.10
-65.81%
1,325.20
Other Short Term Investments
7,201.80
+2.56%
7,021.70
+43.73%
4,885.30
+2479.36%
189.40
Receivables
984.90
-35.37%
1,523.90
-34.87%
2,339.70
-67.26%
7,146.00
Accounts Receivable
924.20
-36.87%
1,463.90
-32.09%
2,155.70
-69.83%
7,145.60
Other Receivables
8.10
-19.00%
10.00
+104.08%
4.90
—
Taxes Receivable
52.60
+5.20%
50.00
-72.08%
179.10
+44675.00%
0.40
Inventory
110.70
-60.92%
283.30
-20.80%
357.70
-18.63%
439.60
Raw Materials
98.10
-63.41%
268.10
-22.85%
347.50
-15.18%
409.70
Work In Process
6.70
-8.22%
7.30
+82.50%
4.00
-80.95%
21.00
Finished Goods
5.90
-25.32%
7.90
+27.42%
6.20
-30.34%
8.90
Current Deferred Assets
—
—
—
—
Other Current Assets
173.80
-18.29%
212.70
-24.28%
280.90
+3.31%
271.90
Total Non Current Assets
5,842.00
+56.78%
3,726.20
+7.11%
3,479.00
+156.36%
1,357.10
Net PPE
1,291.10
+9.10%
1,183.40
+21.80%
971.60
+18.33%
821.10
Gross PPE
1,766.60
+17.32%
1,505.80
+27.24%
1,183.40
+26.24%
937.40
Accumulated Depreciation
-475.50
-47.49%
-322.40
-52.22%
-211.80
-82.12%
-116.30
Properties
0.00
0.00
0.00
0.00
Land And Improvements
586.40
+58.74%
369.40
+56.92%
235.40
+8.48%
217.00
Buildings And Improvements
202.20
-15.11%
238.20
+13.54%
209.80
+1.60%
206.50
Machinery Furniture Equipment
—
—
—
—
Construction In Progress
478.50
+3.89%
460.60
+18.25%
389.50
+65.39%
235.50
Other Properties
499.50
+14.15%
437.60
+25.49%
348.70
+25.25%
278.40
Goodwill And Other Intangible Assets
1,973.90
+68.57%
1,171.00
+0.38%
1,166.60
+431.00%
219.70
Goodwill
367.90
-3.34%
380.60
+4.99%
362.50
+492.32%
61.20
Other Intangible Assets
1,606.00
+103.19%
790.40
-1.70%
804.10
+407.32%
158.50
Investments And Advances
2,554.20
+103.68%
1,254.00
+6.62%
1,176.10
+1366.46%
80.20
Non Current Accounts Receivable
2.00
-79.59%
9.80
—
—
Non Current Deferred Assets
13.50
-83.48%
81.70
+0.49%
81.30
-64.59%
229.60
Non Current Deferred Taxes Assets
13.50
-83.48%
81.70
+0.49%
81.30
-64.59%
229.60
Other Non Current Assets
7.30
-72.24%
26.30
-68.47%
83.40
+1183.08%
6.50
Total Liabilities Net Minority Interest
2,764.40
-11.36%
3,118.60
+12.98%
2,760.40
-14.37%
3,223.50
Current Liabilities
2,142.30
-15.10%
2,523.20
+21.86%
2,070.50
-29.83%
2,950.60
Payables And Accrued Expenses
600.50
+39.26%
431.20
-50.97%
879.50
+9.94%
800.00
Payables
600.50
+39.26%
431.20
-50.97%
879.50
+9.94%
800.00
Accounts Payable
534.90
+25.36%
426.70
+20.54%
354.00
+73.44%
204.10
Total Tax Payable
65.60
+1357.78%
4.50
-99.14%
525.50
-11.81%
595.90
Income Tax Payable
65.60
+1357.78%
4.50
-99.14%
525.50
-11.81%
595.90
Current Debt And Capital Lease Obligation
52.20
+32.15%
39.50
+40.57%
28.10
-21.94%
36.00
Current Debt
52.20
+32.15%
39.50
+40.57%
28.10
-21.94%
36.00
Other Current Borrowings
52.20
+32.15%
39.50
+40.57%
28.10
-21.94%
36.00
Current Deferred Liabilities
754.90
+155.99%
294.90
-16.53%
353.30
+358.24%
77.10
Current Deferred Revenue
754.90
+155.99%
294.90
-16.53%
353.30
+358.24%
77.10
Other Current Liabilities
589.40
-63.45%
1,612.80
+198.50%
540.30
-67.17%
1,645.90
Total Non Current Liabilities Net Minority Interest
622.10
+4.48%
595.40
-13.70%
689.90
+152.80%
272.90
Long Term Debt And Capital Lease Obligation
215.20
+0.23%
214.70
+12.41%
191.00
+8.40%
176.20
Long Term Debt
215.20
+0.23%
214.70
+12.41%
191.00
+8.40%
176.20
Long Term Provisions
35.50
+69.86%
20.90
+137.50%
8.80
+2.33%
8.60
Tradeand Other Payables Non Current
—
—
0.00
-100.00%
10.40
Non Current Deferred Liabilities
172.30
-23.56%
225.40
-48.56%
438.20
+702.56%
54.60
Non Current Deferred Revenue
88.00
-51.91%
183.00
-54.08%
398.50
+723.35%
48.40
Non Current Deferred Taxes Liabilities
84.30
+98.82%
42.40
+6.80%
39.70
+540.32%
6.20
Other Non Current Liabilities
199.10
+48.14%
134.40
+158.96%
51.90
+124.68%
23.10
Stockholders Equity
19,224.20
-0.96%
19,411.10
-4.12%
20,245.90
+0.95%
20,055.60
Common Stock Equity
19,224.20
-0.96%
19,411.10
-4.12%
20,245.90
+0.95%
20,055.60
Capital Stock
259.00
+4.18%
248.60
+0.00%
248.60
+0.00%
248.60
Common Stock
259.00
+4.18%
248.60
+0.00%
248.60
+0.00%
248.60
Share Issued
259.03
+4.21%
248.55
+0.00%
248.55
+0.00%
248.55
Ordinary Shares Number
251.33
+4.73%
239.97
+0.94%
237.73
-2.26%
243.22
Treasury Shares Number
7.70
-10.25%
8.58
-20.74%
10.83
+102.86%
5.34
Additional Paid In Capital
2,473.30
+76.84%
1,398.60
+13.76%
1,229.40
-32.75%
1,828.20
Retained Earnings
17,961.90
-5.95%
19,098.00
-3.37%
19,763.30
+4.94%
18,833.00
Gains Losses Not Affecting Retained Earnings
-1,462.30
-10.32%
-1,325.50
-34.62%
-984.60
-15.99%
-848.90
Treasury Stock
7.70
-10.47%
8.60
-20.37%
10.80
+103.77%
5.30
Other Equity Adjustments
-1,462.30
-10.32%
-1,325.50
-34.62%
-984.60
-15.99%
-848.90
Total Equity Gross Minority Interest
19,224.20
-0.96%
19,411.10
-4.12%
20,245.90
+0.95%
20,055.60
Total Capitalization
19,439.40
-0.95%
19,625.80
-3.97%
20,436.90
+1.01%
20,231.80
Working Capital
14,004.30
-13.98%
16,280.30
-6.74%
17,456.80
-7.98%
18,971.40
Invested Capital
19,491.60
-0.88%
19,665.30
-3.91%
20,465.00
+0.97%
20,267.80
Total Debt
267.40
+5.19%
254.20
+16.02%
219.10
+3.25%
212.20
Net Tangible Assets
17,250.30
-5.43%
18,240.10
-4.40%
19,079.30
-3.81%
19,835.90
Tangible Book Value
17,250.30
-5.43%
18,240.10
-4.40%
19,079.30
-3.81%
19,835.90
Available For Sale Securities
2,554.20
+103.68%
1,254.00
+6.62%
1,176.10
+1366.46%
80.20
Current Provisions
145.30
+0.35%
144.80
-46.23%
269.30
-31.23%
391.60
Investmentin Financial Assets
2,554.20
+103.68%
1,254.00
+6.62%
1,176.10
+1366.46%
80.20
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
456.00
+119.55%
207.70
-96.13%
5,371.40
-60.44%
13,577.40
Cash Flow From Continuing Operating Activities
456.00
+119.55%
207.70
-96.13%
5,371.40
-60.44%
13,577.40
Net Income From Continuing Operations
-1,050.80
-55.05%
-677.70
-157.14%
1,186.10
-90.84%
12,954.10
Depreciation Amortization Depletion
382.80
+28.46%
298.00
+62.49%
183.40
+48.74%
123.30
Depreciation
382.80
+28.46%
298.00
+62.49%
183.40
+48.74%
123.30
Amortization Cash Flow
—
—
40.50
+84.09%
22.00
Depreciation And Amortization
382.80
+28.46%
298.00
+62.49%
183.40
+48.74%
123.30
Amortization Of Intangibles
—
—
40.50
+84.09%
22.00
Other Non Cash Items
169.70
+124.20%
-701.10
+45.03%
-1,275.50
-328.16%
-297.90
Stock Based Compensation
106.20
+5.25%
100.90
+96.30%
51.40
-52.67%
108.60
Operating Gains Losses
-19.50
+81.46%
-105.20
+11.37%
-118.70
-130.82%
385.10
Gain Loss On Investment Securities
-10.40
-326.09%
4.60
-97.38%
175.50
+172.82%
-241.00
Net Foreign Currency Exchange Gain Loss
-6.60
+93.97%
-109.50
+63.26%
-298.00
-147.64%
625.50
Gain Loss On Sale Of PPE
-2.50
-733.33%
-0.30
-107.89%
3.80
+533.33%
0.60
Change In Working Capital
537.80
-55.94%
1,220.60
-78.11%
5,574.80
+23.38%
4,518.50
Change In Receivables
1,083.70
+179.52%
387.70
-92.79%
5,374.00
+22.98%
4,369.90
Changes In Account Receivables
—
—
—
4,369.90
Change In Inventory
177.90
+138.79%
74.50
-9.04%
81.90
+30.21%
62.90
Change In Payables And Accrued Expense
-723.80
-195.44%
758.40
+537.85%
118.90
+38.74%
85.70
Change In Payable
-723.80
-195.44%
758.40
+537.85%
118.90
+38.74%
85.70
Change In Account Payable
-723.80
-195.44%
758.40
+537.85%
118.90
+38.74%
85.70
Investing Cash Flow
-2,468.50
-18.61%
-2,081.20
+70.07%
-6,954.50
-19601.13%
-35.30
Cash Flow From Continuing Investing Activities
-2,468.50
-18.61%
-2,081.20
+70.07%
-6,954.50
-19601.13%
-35.30
Net PPE Purchase And Sale
-170.60
+40.20%
-285.30
-14.07%
-250.10
+23.89%
-328.60
Purchase Of PPE
-175.10
+38.88%
-286.50
-14.55%
-250.10
+24.03%
-329.20
Sale Of PPE
4.50
+275.00%
1.20
—
0.60
Capital Expenditure
-749.00
-65.60%
-452.30
+35.89%
-705.50
-94.19%
-363.30
Net Investment Purchase And Sale
-1,910.30
-17.19%
-1,630.10
+72.43%
-5,912.10
-1905.77%
327.40
Purchase Of Investment
-11,422.50
+7.66%
-12,370.30
-73.54%
-7,128.40
-14812.97%
-47.80
Sale Of Investment
9,512.20
-11.43%
10,740.20
+783.02%
1,216.30
+224.17%
375.20
Net Business Purchase And Sale
186.30
0.00
+100.00%
-336.90
0.00
Purchase Of Business
—
0.00
+100.00%
-336.90
0.00
Net Intangibles Purchase And Sale
-573.90
-246.14%
-165.80
+63.59%
-455.40
-1235.48%
-34.10
Purchase Of Intangibles
-573.90
-246.14%
-165.80
+63.59%
-455.40
-1235.48%
-34.10
Financing Cash Flow
-52.90
-15.25%
-45.90
+94.10%
-778.60
+45.14%
-1,419.30
Cash Flow From Continuing Financing Activities
-52.90
-15.25%
-45.90
+94.10%
-778.60
+45.14%
-1,419.30
Net Issuance Payments Of Debt
-50.90
-10.89%
-45.90
-14.46%
-40.10
+32.15%
-59.10
Issuance Of Debt
6.70
0.00
-100.00%
0.30
-62.50%
0.80
Repayment Of Debt
-57.60
-25.49%
-45.90
-13.61%
-40.40
+32.55%
-59.90
Long Term Debt Issuance
6.70
0.00
-100.00%
0.30
-62.50%
0.80
Long Term Debt Payments
-57.60
-25.49%
-45.90
-13.61%
-40.40
+32.55%
-59.90
Net Long Term Debt Issuance
-50.90
-10.89%
-45.90
-14.46%
-40.10
+32.15%
-59.10
Net Common Stock Issuance
0.00
0.00
+100.00%
-738.50
+15.69%
-875.90
Common Stock Payments
0.00
0.00
+100.00%
-738.50
+25.13%
-986.40
Cash Dividends Paid
—
0.00
0.00
+100.00%
-484.30
Repurchase Of Capital Stock
0.00
0.00
+100.00%
-738.50
+25.13%
-986.40
Net Other Financing Charges
-2.00
—
—
—
Changes In Cash
-2,065.40
-7.61%
-1,919.40
+18.73%
-2,361.70
-119.48%
12,122.80
Effect Of Exchange Rate Changes
-27.00
-282.43%
14.80
+202.07%
-14.50
-124.13%
60.10
Beginning Cash Position
9,761.90
-16.31%
11,663.70
-15.94%
13,875.10
+719.70%
1,692.70
End Cash Position
7,675.40
-21.37%
9,761.90
-16.31%
11,663.70
-15.94%
13,875.10
Free Cash Flow
-293.00
-19.79%
-244.60
-105.24%
4,665.90
-64.69%
13,214.10
Common Stock Issuance
—
0.00
0.00
-100.00%
110.50
Interest Paid CFO
-11.00
+18.52%
-13.50
-150.00%
-5.40
+74.88%
-21.50
Interest Received CFO
337.00
-29.04%
474.90
+83.93%
258.20
+781.23%
29.30
Issuance Of Capital Stock
—
0.00
0.00
-100.00%
110.50
Other Cash Adjustment Outside Changein Cash
5.90
+110.71%
2.80
-98.30%
164.80
+33060.00%
-0.50
Sale Of Business
186.30
—
—
0.00
Taxes Refund Paid
3.80
+100.98%
-389.20
+19.40%
-482.90
+88.56%
-4,222.10
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category